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ARTICLE
Collagen prolyl 4-hydroxylase 1 is essential for
HIF-1α stabilization and TNBC chemoresistance
Gaofeng Xiong1,2, Rachel L. Stewart 3, Jie Chen1,2, Tianyan Gao1,4, Timothy L. Scott5,6, Luis M. Samayoa3,
Kathleen O’Connor1,4, Andrew N. Lane5,6 & Ren Xu 1,2
Collagen prolyl 4-hydroxylase (P4H) expression and collagen hydroxylation in cancer cells
are necessary for breast cancer progression. Here, we show that P4H alpha 1 subunit
(P4HA1) protein expression is induced in triple-negative breast cancer (TNBC) and HER2
positive breast cancer. By modulating alpha ketoglutarate (α-KG) and succinate levels P4HA1
expression reduces proline hydroxylation on hypoxia-inducible factor (HIF) 1α, enhancing its
stability in cancer cells. Activation of the P4HA/HIF-1 axis enhances cancer cell stemness,
accompanied by decreased oxidative phosphorylation and reactive oxygen species (ROS)
levels. Inhibition of P4HA1 sensitizes TNBC to the chemotherapeutic agent docetaxel and
doxorubicin in xenografts and patient-derived models. We also show that increased P4HA1
expression correlates with short relapse-free survival in TNBC patients who received che-
motherapy. These results suggest that P4HA1 promotes chemoresistance by modulating HIF-
1-dependent cancer cell stemness. Targeting collagen P4H is a promising strategy to inhibit
tumor progression and sensitize TNBC to chemotherapeutic agents.
DOI: 10.1038/s41467-018-06893-9 OPEN
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Prolyl hydroxylation, a common post-translational mod-ification, modulates protein folding and stability in mam-malian cells. The abundance of hydroxyproline among the
residues in animal proteins is about 4%, and most of the
hydroxyproline is found within the collagen1,2. Collagen prolyl 4-
hydroxylase (P4H) is an α2β2 tetrameric α-ketoglutarate (α-KG)-
dependent dioxygenase that catalyzes 4-hydroxylation of proline
to promote formation of the collagen triple helix, releasing suc-
cinate as a product3. The P4H αsubunit (P4HA) is responsible for
both peptide binding and catalytic activity. This process can be
blocked by a number of inhibitors. Three P4HA isoforms
(P4HA1-3) have been identified in mammalian cells2. P4HA1 is
the major isoform in most cell types and tissues, and contributes
to the majority of the prolyl 4-hydroxylase activity4. Increased
collagen production is associated with breast cancer development
and progression, and stromal cells are the major source of col-
lagen deposition5,6. The expression of collagen P4H is sig-
nificantly upregulated during breast cancer development and
progression, and increased P4HA expression correlates with poor
prognosis7,8. Interestingly, induction of P4HA1 expression in
cancer cells is required for breast cancer metastasis7. However, we
know little about how cancer cell P4HA1 promotes tumor
progression.
High levels of hypoxia-inducible factor-1α (HIF-1α) are asso-
ciated with advanced cancer progression and poor clinical out-
comes in breast cancer patients9,10. Activation of the HIF-1
pathway induces metabolic reprogramming and enhances
angiogenesis, which is crucial for cancer progression11,12. De
novo synthesized HIF-1α is rapidly hydroxylated by a family of
oxygen-dependent dioxygenases (PHD) on proline 402 (Pro402)
and proline 564 (Pro564)13–15. Proline hydroxylation induces
HIF-1α ubiquitination and degradation, and subsequently redu-
ces the half-life of HIF-1 protein14,16. The prolyl hydroxylation
on HIF-1α is regulated by the concentration of the substrate
oxygen17,18. Hyperactive HIF-1 pathway has been detected in
triple-negative breast cancers (TNBCs)19,20. The differential
activation of the HIF-1 pathway in breast cancer subtypes sug-
gests that oxygen-independent pathways are involved in HIF-1α
regulation during TNBC progression. However, the molecular
mechanism underlying the HIF-1 activation in TNBC is not
completely understood.
TNBC is an aggressive histological subtype with poor prognosis
and accounts for approximately 15% of all breast cancer cases21.
Patients with this cancer subtype have frequent metastases and a
high rate of relapse after the first-line treatment21–23. Because TNBC
is estrogen receptor (ER) negative, progesterone receptor (PR)
negative, and Her2 negative, it is not responsive to hormone therapy
and to drugs that target the HER2 protein. Chemotherapy regimens
are standard of care treatment for TNBC, but more than 50% of
patients are likely to experience cancer recurrence in the first 3 to 5
years after treatment24. Recent studies suggest that the activation of
the HIF-1 pathway promotes chemoresistance in breast cancer25,26.
Therefore, targeting the HIF-1 pathway is a potential strategy to
suppress TNBC progression and chemoresistance.
Increased collagen deposition is associated with breast cancer
development and progression, and stromal cells are considered
the major source of collagen deposition5. Surprisingly, we and
others have shown that increased expression of collagen prolyl 4-
hydroxylase in breast cancer cells is required for cancer
progression7,8. However, the critical molecular mechanisms that
P4HA expression in cancer cells induces cancer progression have
not been characterized. In the present study, we have identified a
link between collagen hydroxylation and HIF-1 activation during
TNBC progression. Our results suggest that inhibition of P4HA1
is a potential strategy to sensitize TNBC to chemotherapeutic
agents.
Results
P4HA1 expression is associated with HIF-1 activation. To
define the roles of P4HA1 in breast cancer progression, we ana-
lyzed P4HA1 protein levels in human breast cancer tissue using
tissue microarrays generated at UKY. We showed that P4HA1
expression was upregulated in TNBC and HER2-positive breast
cancer tissues compared to the ER-positive breast cancer (Fig. 1a,
b). P4HA1-positive staining was significantly enriched in high-
stage TNBC tissues (Fig. 1c), indicating that P4HA1 expression is
associated with TNBC progression. We also found that P4HA1
protein levels were increased in TNBC cell lines compared to
luminal cancer cells (Fig. 1d). The upregulation of P4HA1 in
breast cancer cell lines is associated with increased secretion of
collagen (Fig. 1d).
Reducing P4HA1 expression or blocking its activity with
P4H inhibitors (P4Hi) significantly represses tumor progres-
sion in the three-dimensional (3D) culture system (Supple-
mentary Fig. 1a–f) and xenograft models7,8. To elucidate the
molecular mechanisms by which P4HA1 promotes cancer
progression, we performed unbiased gene co-expression and
gene ontology analysis27 using the breast cancer The Cancer
Genome Atlas gene expression dataset. This analysis revealed
that P4HA1 levels were positively correlated with gene
expression signatures involved in response to hypoxia and
glycolysis (Fig. 2a) (Supplementary Table 1). These data
implicate that P4HA1 expression contributes to the hypoxic
response and glycolysis during cancer development. HIF-1 is a
key mediator of the hypoxic response and a pivotal regulator of
the balance between lactic fermentation and pyruvate oxida-
tion. We therefore tested whether the expression of P4HA1
induces the HIF-1 pathway in mammary epithelial cells.
Introduction of exogenous P4HA1 with its cofactor P4HB
increased HIF-1α protein levels in MCF10A and HMLE cell
lines under both normoxia and hypoxia conditions (Fig. 2b, c).
Quantitative reverse transcription-PCR (RT-PCR) data showed
that P4HA1 expression had little effect on HIF-1α messenger
RNA (mRNA) levels (Supplementary Fig. 2a), suggesting that
the regulation is at the protein level. Knockdown of P4HA1 in
TNBC cell lines reduced HIF-1α protein levels under both
normoxia and hypoxia conditions (Fig. 2d, e). The expression
of P4HA1 in P4HA1-silenced cells restored the HIF-1α levels
(Supplementary Fig. 2b). We also found that secretion of
collagen is regulated by P4HA1 in mammary epithelial cells
(Supplementary Fig. 2c). In addition, treatment with P4HA
inhibitor 1,4-dihydrophenonthrolin-4-one-3-carboxylic acid
(1,4-DPCA) or ethyl-3,4-dihydroxybenzoic acid decreased
HIF-1α protein levels in breast cancer cells (Fig. 2f).
To determine whether HIF-1 activity is regulated by P4HA1,
we introduced the hypoxia response element (HRE)-luciferase
reporter plasmid in control and P4HA1-silenced cells. The
reporter data showed that knockdown of P4HA1 significantly
reduced transcription driven by HRE (Fig. 2g), and treatment
with the P4Hi also reduced the HRE-driven luciferase activity
(Supplementary Fig. 2d). Next, we assessed expression of HIF-1
target genes lactate dehydrogenase A (LDHA) and pyruvate
dehydrogenase kinase 1 (PDK1) in control, P4HA1-silenced, and
P4HA1-expressing mammary epithelial cells. Quantitative RT-
PCR data showed that silencing P4HA1 in breast cancer cells
significantly reduced mRNA levels of LDHA and PDK1 under
normoxia and hypoxia conditions (Fig. 2h). In contrast,
expression of P4HA1 in MCF10A cells enhanced LDHA and
PDK1 expression (Fig. 2i). In addition, P4HA1 expression
significantly correlated with mRNA levels of LDHA and PDK1
in human breast cancer tissue (Supplementary Fig. 2e and 2f).
These results indicate that P4HA1 expression in breast cancer
cells induces activation of the HIF-1 pathway.
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Collagen hydroxylation enhances HIF-1α stability. In the pre-
sence of active PHD, HIF-1α protein is hydroxylated and targeted
for degradation by the ubiquitin–proteasome system28, which
dramatically reduces the half-life of HIF-1 protein14,16. Since
P4HA1 expression had little effect on HIF-1α mRNA levels, we
determined whether P4HA1 regulates HIF-1α protein stability.
We performed a time-course experiment to determine HIF-1α
protein degradation in control and P4HA1-silenced cells after
cycloheximide treatment. We found that knockdown of
P4HA1 significantly increased HIF-1α protein degradation at the
early time points (Fig. 3a–d). HIF-1α ubiquitination was also
upregulated in P4HA1-silenced cells (Fig. 3e). Importantly,
treatment with the proteasome inhibitor Bortezomib rescued
HIF-1α protein expression in P4HA1-silenced breast cancer cells
(Fig. 3f). These results suggest that P4HA1 increases HIF-1α
protein levels by reducing ubiquitination-mediated protein
degradation.
Using the antibody against hydroxylated HIF-1α (P402), we
showed that silencing P4HA1 drastically increased HIF-1α
hydroxylation in MDA-MB-231 cells, while expression of
P4HA1 and P4HB reduced proline hydroxylation in MCF10A
cells (Fig. 3g). The ODD-luciferase reporter construct consisting
of a firefly luciferase gene fused to the hydroxylation-dependent
degradation region of HIF-1α has been used to monitor HIF-1α
stability/degradation29. Using this reporter assay, we showed that
expression of P4HA1 and P4HB significantly induced ODD-
luciferase activity in MCF10A cells under normoxia and hypoxia
conditions (Fig. 3h). In contrast, silencing P4HA1 reduced ODD-
luciferase activity in MDA-MB-231 cells (Fig. 3i). It has been
shown that point mutation on P402 and P564 on HIF-1α reduces
proline hydroxylation and significantly increases protein stability;
therefore, we introduced proline hydroxylation-deficient HIF-1α
PPAA in P4HA1-silenced cells. We found that the HIF-1α PPAA
mutant, but not wild-type HIF-1α, rescued HIF-1α expression
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(Fig. 3j). These results strongly support the hypothesis that
P4HA1 enhances HIF-1α protein stability by reducing proline
hydroxylation.
We showed that silencing P4HA1 had little effect on the
protein level of PHD1 and PHD3 and slightly reduced the PHD2
protein level (Supplementary Fig. 3a), suggesting that induced
HIF-1α hydroxylation is not due to increased PHD expression. In
addition, silencing PHD2 but not PHD1 restored HIF-1α protein
levels in P4HA1-silenced MDA-MB-231 cells (Supplementary
Fig. 3b, c). These experiments indicate that P4HA1 increases the
HIF-1α protein level by reducing PHD2-dependent proline
hydroxylation. Silencing P4HA1 reduced HIF-1α levels in both
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normoxia and hypoxia conditions (Fig. 2d, e), indicating that
P4HA1-induced HIF-1α stabilization is independent of oxygen.
These results suggest that the P4HA1 expression may affect the
activity of PHD by changing either the concentration of the co-
substrate α-KG and/or the product succinate or related
metabolites (Fig. 4a). It has been reported that the PHD Km
value for α-KG is about 3-fold relative to P4HA130. We therefore
determined whether P4HA1 reduces proline hydroxylation on
HIF-1α by modulating α-KG levels in cytoplasm. We have used
stable isotope resolved metabolomics (SIRM) that combines the
use of stable isotope tracers with mass spectrometric (MS) and
nuclear magnetic resonance (NMR) analyses31,32, to determine
the levels and 13C incorporation into various metabolites. The
levels of α-KG were increased in P4HA1-silenced MDA-MB-231
cells (Fig. 4b). We further confirmed that knockdown of
P4HA1 significantly increased cytoplasmic α-KG levels in
MDA-MB-231, Hs578T, and MDA-MB-157 cell lines with the
α-KG quantification assay (Fig. 4c). In contrast, expression of
P4HA1/P4HB significantly reduced cytoplasmic α-KG levels in
MCF10A cells (Fig. 4d). The hydroxylation process on collagen
requires α-KG as a co-substrate, and the reaction also generates a
stoichiometric amount of succinate3. In fact, silencing
P4HA1 significantly reduced succinate levels in the cytoplasm
of breast cancer cells (Fig. 4e). The changes of α-KG and
succinate in P4HA1-silenced cells can be restored by P4AH1
expression (Supplementary Fig. 4a, b).
We performed two rescue experiments to determine whether
α-KG and succinate mediate P4HA1-induced HIF-1α protein
stabilization. Incubation of P4HA1-expressing MCF10A cells
with octyl-α-ketoglutarate, a cell-permeable form of α-KG33,
reduced HIF-1α protein levels (Fig. 4f). Treatment with dimethyl-
succinate slightly increased HIF-1α protein levels in P4HA1-
silenced breast cancer cells (Fig. 4g). Using the ODD-luciferase
reporter assay, we showed that treatment with octyl-α-
ketoglutarate reduced the luciferase activity induced by P4HA1
(Fig. 4h), whereas dimethyl-succinate significantly increased
luciferase activity in P4HA1-silenced cells (Fig. 4i). Consuming
α-KG and generating succinate during collagen hydroxylation is
dependent on the hydroxylase activity of P4HA1. We found that
expressing hydroxylation-deficient P4HA1 mutants failed to
induce HIF-1α at the protein levels (Fig. 4j). These results
indicate that P4HA1 activates the HIF-1 pathway by reducing
HIF-1α degradation, and this regulation is mediated by the
metabolites α-KG and succinate.
P4HA1 regulates cancer cell stemness through HIF-1. Tumor-
initiating cells are enriched in the CD44+/CD24–/low cell popu-
lation34–36. We isolated a number of CD44+/CD24–/low and
CD44low/CD24+ clones from HMLE cells36 (Fig. 5a). P4HA1 and
HIF-1α expression was upregulated in CD44+/CD24–/low clones
(Fig. 5b). The tumorsphere assay has been used to enrich tumor-
initiating cells and study their colony formation activity37. By
comparing gene expression profiles generated from tumorsphere
and their matched primary human breast cancer tissue38, we
found that mRNA levels of P4HA1 were significantly increased in
tumorspheres (Fig. 5c). Importantly, CD44+/CD24–/low cell
population was decreased in P4HA1-silenced MDA-MB-231 cells
(Fig. 5d). Knockdown of P4HA1 significantly inhibited tumor-
sphere formation in Hs578T, MDA-MB-231, and MDA-MB-157
cell lines (Fig. 5e, f). In contrast, expression of P4HA1 and P4HB
promoted mammosphere formation in MCF10A cells (Fig. 5g),
while treatment with octyl-α-ketoglutarate inhibited P4HA1-
induced mammosphere formation in MCF10A cells (Fig. 5g). We
also found that expression of the HIF-1α PPAA mutant restored
tumorsphere formation in P4HA1-silenced cancer cells (Fig. 5h).
Enhanced aldehyde dehydrogenase (ALDH) activity is a marker
of tumor-initiating cells39. Using the ALDEFLUOR™ assay and
fluorescence-activated cell sorting (FACS), we showed that
ALDH-high cell population was significantly reduced in P4HA1-
silenced MDA-MB-231 cells, while expression of HIF-1α PPAA
mutant in P4HA1-silenced cells rescued ALDH-high cell popu-
lation (Fig. 5i). We also showed that expression of P4HA1 in
P4HA1-silenced cells restored the tumorsphere formation and
ALDH-high cell population (Supplementary Fig. 5a, b). These
results suggest that activation of the P4HA1/HIF-1 pathway is
crucial for stemness properties in breast cancer cells.
Reactive oxygen species (ROS) levels and oxidative phos-
phorylation are decreased in stem cells40,41, and the decrease is
crucial for the maintenance of stemness. We found that
knockdown of P4HA1 in MDA-MB-231 cells elevated the
oxygen consumption rate (OCR), indicating that oxidative
phosphorylation is enhanced in P4HA1-silenced cells (Fig. 5j,
k). In contrast, expression of P4HA1 and P4HB in MCF10A
cells increased extracellular acidification rate (ECAR) and
reduced OCR levels (Supplementary Fig. 5c, d). The upregula-
tion of respiration in P4HA1-silenced cells was accompanied by
increased ROS levels (Fig. 5l), which can be rescued by P4AH1
expression (Supplementary Fig. 5e). Expression of HIF-1α
PPAA in P4HA1-silenced MDA-MB-231 cells significantly
reduced ROS production and repressed oxygen consumption
under both basal and maximal respiration conditions (Fig. 5k,
l), indicating that P4HA1 regulates ROS and oxidative
phosphorylation through the HIF-1 pathway. We also found
that silence of P4HA1 reduced ECAR in breast cancer cells, and
HIF-1α PPAA mutant restored ECAR in P4HA1-silenced cells
(Supplementary Fig. 5f). These results suggest that upregulation
of P4HA1 contributes to glycolysis in breast cancer cells. It has
been shown that HIF-1 target genes LDHA and PDK1 repress
oxidative phosphorylation and ROS production42–45. Consis-
tently, we found that expression of the HIF-1α PPAA mutant
restored the expression of LDHA and PDK1 in P4HA1-silenced
cells (Supplementary Fig. 5g). Collectively, P4HA1 may regulate
cancer cell stemness through HIF-1-dependent metabolic
reprogramming.
Inhibition of P4HA1 sensitizes TNBC to chemotherapy. One
crucial role for tumor-initiating cells in cancer progression is to
facilitate metastatic colonization. We showed that increased
P4HA1 expression in primary tumors was associated with a short
distant metastasis-free survival in breast cancer patients
Fig. 2 P4HA1 induces the HIF-1 pathway in breast cancer cells. a Gene co-expression and gene ontology analyses of the gene signature associated with
P4HA1 expression in human breast cancer tissue. b, cWestern blot analyses of HIF-1α expression in P4HA1-expressing MCF10A and HMLE cell lines under
normoxia and hypoxia conditions. d, e HIF-1α protein levels were assessed in control and P4HA1-silenced TNBC cell lines under normoxia and hypoxia
conditions. f HIF-1α protein levels in MDA-MB-231 cells after P4HA inhibitor 1,4-DPCA or ethyl-3,4-dihydroxybenzoic acid (DHB) treatment. g HRE
reporter analysis of the HIF-1 activity in control and P4HA1-silenced 293FT cells under normoxia and hypoxia conditions. Results are presented as mean ±
SEM; n= 3; **p < 0.01, one-way ANOVA test. h, i Quantitative RT-PCR measuring mRNA levels of HIF-1 target genes lactate dehydrogenase A (LDHA) and
pyruvate dehydrogenase kinase 1 (PDK1) in control, P4HA1-silenced MDA-MB-231 cells, and P4HA1-expressing MCF10A cells under normoxia and
hypoxia conditions. Results are presented as mean ± SEM; n= 4; *p < 0.05, **p < 0.01, independent Student’s t test
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(Supplementary Fig. 6a). Therefore, we asked whether silencing
P4HA1 inhibits lung colonization of MDA-MB-231 cells. Control
and P4HA1-silenced MDA-MB-231 (luciferase-expressing) cells
were injected in severe combined immunodeficiency (SCID) mice
via tail vein. The cancer cell colonization in secondary organs was
monitored by In Vivo Imaging System Facility (IVIS) imaging.
We found that knockdown of P4HA1 significantly reduced
colonization of MDA-MB-231 cells in lung and other organs
(Fig. 6a, b) and the level of HIF-1α protein in metastasis lesions
(Supplementary Fig. 6b).
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The increased tumor-initiating cell population in cancer tissue
has been linked with chemoresistance26,38,46. Consistently, we
found that stem cell-enriched CD44+/CD24–/low HMLE clones
were more resistant to doxorubicin (DOX) and docetaxel (DOC)
treatment (Fig. 6c). These clones exhibited increased P4HA1
expression (Fig. 5a, b). More importantly, silencing P4HA1 or
treatment with the P4HA inhibitor sensitized the CD44+/CD24–/
low clones and MDA-MB-231 cells to DOX or DOC (Fig. 6d–f),
while inhibition of P4HA1 in CD44low/CD24+ clones did not
significantly increase their sensitivity to DOC and DOX
(Supplementary Fig. 6c). We also found that DOC or DOX
treatment enhanced tumorsphere formation in MDA-MB-231
cells (Fig. 6g). Treatment with DOC or DOX for 7 days also
induced P4HA1 expression (Supplementary Fig. 6d). These results
suggest that chemotherapy may enrich cancer stem cells with high
levels of P4HA1. Platin salt is another common chemotherapy
agent for breast cancer. Silencing P4HA1 or treatment with the
P4Hi also sensitized MDA-MB-231 cells to cisplatin (Supplemen-
tary Fig. 6e, f). Silencing P4HA1 or treatment with P4Hi reduced
DOC-induced tumorsphere formation (Fig. 6g, h). Therefore,
inhibition of P4HA1 may sensitize TNBC to chemotherapeutic
agents by inhibiting cancer cell stemness.
To determine in vivo function of P4HA1 in regulating
chemoresistance, we transplanted control and P4HA1-silenced
MDA-MB-231 cells into mammary fat pads of female SCID mice.
Treatment with DOC-induced regression in P4HA-silenced
tumors, but only inhibited tumor growth in the control group
(Fig. 7a). The DOC treatment was stopped after three weeks, and
tumor regrowth was significantly delayed in the P4HA1-silenced
group (Fig. 7a). We showed that CD44+CD24− cell population
was reduced in P4HA1-silenced groups with or without DOC
treatment (Supplementary Fig. 7a). These results suggest that
inhibition of P4HA1 reduces the tumor-initiating cell population
in vivo. Silence of P4HA1 in HIF-1α PPAA-expressing MDA-
MB-231 cells did not significantly sensitize the xenograft to DOC
treatment (Supplementary Fig. 7b), suggesting that P4HA1
promotes chemoresistance at least partially through the HIF-1
pathway.
Ethyl-3,4-dihydroxybenzoic acid (DHB) is a selective collagen
P4Hi30 and has been safely used in mice7. To determine whether
inhibition of P4HA activity sensitizes TNBC to chemotherapeutic
reagents, MDA-MB-231 cells were implanted in mammary fat
pad, and then treated with DHB and/or DOC. Treatment with
DHB only slightly inhibited tumor growth, but DHB significantly
enhanced the inhibitory activity of DOC (Fig. 7b). We showed
that the combined treatment induced tumor repression (Fig. 7b).
We also noticed that the P4Hi was more potent to inhibit primary
tumor growth. P4HA family includes P4HA1, P4HA2, and
P4HA32. DHB may target other P4HA family members. It is
possible that P4Hi treatment suppresses tumor growth by
inhibiting other P4HA family members.
Immunohistochemical (IHC) analysis data showed that DHB
significantly enhanced DOC-induced cell apoptosis and growth
arrest in tumor tissues, although DHB alone only slightly
repressed cell proliferation and apoptosis (Fig. 7c–e). We found
that the combined treatment reduced the HIF-1α protein levels
and collagen deposition in tumor tissue (Fig. 7c and Supplemen-
tary Fig. 7c, d). In addition, the combined treatment blocked the
metastasis of MDA-MB-231 cells to the lungs (Fig. 7f). Therefore,
inhibition of P4HA1 expression or its activity is a promising
strategy to sensitize the TNBC xenograft to DOC treatment.
Patient-derived tumor organoids (PDOs) and xenografts
(PDXs) represent powerful tools to study drug response and
drug resistance for cancer treatment because they contain stromal
components and maintain the heterogeneity, differentiation
status, and histopathology of the primary tumor47,48. We showed
that TNBC PDOs grew in the 3D laminin-rich extracellular
matrix (ECM) gel, and DOC or DOX inhibited PDO growth
(Fig. 8a, b). Importantly, treatment with the P4HA inhibitor
significantly enhanced tumor regression induced by chemother-
apeutic agents (Fig. 8a, b). Similar results were also obtained in
primary tumor organoids derived from other TNBC patients
(Supplementary Fig. 8a, b). Using the PDX model, we further
confirmed that treatment with the P4HA inhibitor enhanced the
inhibitory activity of DOC to TNBC in vivo (Fig. 8c) (Supple-
mentary Fig. 8c–d). DHB significantly increased DOC-induced
cell apoptosis and growth arrest in tumor tissues (Supplementary
Fig. 8e–f). The combined treatment also reduced the HIF-1α
protein levels and collagen deposition in tumor tissue (Supple-
mentary Fig. 8e–f).
To address the clinical relevance of enhanced P4HA1
expression, we assessed the association between mRNA levels of
P4HA1 and patient survival using the published microarray data
generated from 581 human TNBC tissue samples49. We found
that increased P4HA1 mRNA levels correlated with short relapse-
free survival in TNBC patients (Fig. 8d). A positive correlation
between increased P4HA1 expression and a high incidence of
recurrence was identified in TNBC patients who received
chemotherapy (Fig. 8e). Using the METABRIC dataset50, we
further confirmed the association between P4HA1 expression and
chemoresistance (Supplementary Fig. 8g). Next, we determined
the association between P4HA1 expression and the activation of
HIF-1 pathway in human breast cancer tissue by analyzing
expression of the HIF-1 gene signature51. Expression of the HIF-1
gene signature was significantly correlated with P4HA1 levels in
human breast cancer tissue (Fig. 8f). Collectively, these results
suggest that activation of the P4HA1/HIF-1 axis is associated with
chemoresistance and a poor clinical outcome in TNBC.
Fig. 5 P4HA regulates cancer cell stemness through the HIF-1 pathway. a, b Expression of HIF-1α, P4HA1, and E-cadherin was assessed in CD44low/CD24+
clones and CD44+/CD24–/low clones. c Quantification of mRNA levels of P4HA1 in primary breast cancer tissue and tumor spheroids derived from those
tissues. The gene expression values were derived from published microarray dataset. The data were log 2 transformed and mean centered. Primary tumor,
n= 11; tumorsphere, n= 15. The median, 10th, 25th, 75th, and 90th percentiles were plotted as vertical boxes with error bars. The data were analyzed by
Mann–Whitney rank-sum test. d FACS analysis of CD44+/CD24–/low population in shCtrl and shP4HA1 MDA-MB-231 cells. Results are presented as mean
± SEM; n= 3; **p < 0.01, independent Student’s t test. e, f Images of tumorspheres and quantification of tumorsphere formation efficiency (TFE) in control or
P4HA1-silenced MDA-MB-231 cells, Hs578t cells, and MDA-MB-157 cells. Results are presented as mean ± SEM; n= 3; **p < 0.01, independent Student’s t
test. g, h Quantification of tumorsphere formation efficiency (TFE) in control, P4HA1-expressing, and P4HA1-silenced cells in the presence or absence of
octyl-α-ketoglutarate or HIF-1α PPAA. Results are presented as mean ± SEM; n= 3, **p < 0.01, one-way ANOVA test. i FACS analysis of aldehyde
dehydrogenase (ALDH) activity in control, P4HA1-silenced MDA-MB-231 cells, and P4HA1-silenced MDA-MB-231 cells with HIF-1α PPAA. Results are
presented as mean ± SEM; n= 3; *p < 0.05; **p < 0.01, one-way ANOVA test. j Seahorse analysis of oxygen consumption rate (OCR) in control, P4HA1-
silenced MDA-MB-231 cells, and P4HA1-silenced MDA-MB-231 cells with HIF-1α PPAA. k Quantification of OCR from j; n= 30; results are presented as
mean ± SEM; **p < 0.01, one-way ANOVA test. l FACS quantification of ROS levels in control or P4HA1-silenced MDA-MB-231 cells in the presence or
absence of HIF-1α PPAA; n= 3, results are presented as mean ± SEM; **p < 0.01, one-way ANOVA test
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Discussion
In the present study, we show that the major role for collagen
hydroxylation enzyme P4HA1 in breast cancer cells is to enhance
HIF-1 protein stability by reducing availability of α-KG and by
producing succinate. Inhibition of the P4HA1/HIF-1 axis sup-
presses stemness in breast cancer cells. We demonstrate that
P4HA1 expression is upregulated in TNBC tissues and correlates
with poor prognosis and chemoresistance in TNBC patients.
Importantly, inhibition of collagen P4H sensitizes TNBC to
chemotherapy. P4HA1 expression is also upregulated in HER2-
positive tumor and cancer cell line (Supplementary Fig. 9a, b).
However, roles of P4HA1 in HER2 cancer progression still need
further clarification. Our findings reveal a novel function of
P4HA1 in promoting TNBC progression through the HIF-1
pathway.
PHD-dependent HIF-1α hydroxylation is enhanced by sub-
strate α-KG and inhibited by succinate3,33,52,53. Mutation of IDH-
1 in glioma induces the HIF-1 pathway by reducing α-KG pro-
duction53. This evidence suggests that metabolites such as α-KG
and succinate also contribute to HIF-1 activation during cancer
development and progression. However, how those metabolites
are regulated in breast cancer to induce hyperactivation of the
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Fig. 6 Inhibition of P4HA1 enhances cell response to chemotherapeutic agents. a, b Colonization of control and P4HA1-silenced MDA-MB-231 cells in the
distance organs were assessed by bioluminescence signals and IHC analysis. Bar: 80 µm. Results are presented as mean ± SEM; n= 6; *p < 0.05. c–e
Quantification of cell number in CD44+/CD24–/low HMLE clones and CD44low/CD24+ HMLE clones after doxorubicin and docetaxel treatment in the
presence or absence of P4HA inhibitor (1,4-DPCA) or shP4HA1. Results are presented as mean ± SEM; n= 3 in c; n= 4 in d, e; *p < 0.05; **p < 0.01, one-
way ANOVA test. f Quantification of cell number in control and P4HA1-silenced MDA-MB-231 cells after doxorubicin treatment. Results are presented as
mean ± SEM; n= 3; **p < 0.01, one-way ANOVA test. g, h Quantification of tumorsphere formation efficiency (TFE) in control or P4HA1-silenced MDA-
MB-231 cells. The cells were treated with doxorubicin, docetaxel, and/or the 1,4-DPCA before the tumorsphere formation assay for 4 days. Results are
presented as mean ± SEM; n= 3; **p < 0.01, one-way ANOVA test
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HIF-1 pathway is unclear. Collagen P4H has 3-fold higher affinity
to α-KG and 6-fold higher affinity to oxygen compared to PHD30.
About 38% of proline in collagen are hydroxylated1, thus
increased expression of collagen P4H may consume a substantial
amount of α-KG and generates succinate. We showed that
P4HA1 protein expression is significantly upregulated in TNBC,
and that the upregulation is associated with TNBC progression.
Importantly, P4HA1 expression significantly reduced α-KG levels
and elevated succinate levels in the cytoplasm, and subsequently
enhanced HIF-1α stability and activity. These findings do not rule
out the possibility that other pathways may also contribute to the
differential activation of the HIF-1 pathway between breast can-
cer subtypes. It has been shown that XBP1 assembles a tran-
scriptional complex with HIF-1α that regulates the expression of
HIF-1α-target genes and subsequently drives TNBC tumor-
igenicity19. In addition, SHARP1 binds to HIFs and promotes
proteasomal degradation of HIFs by serving as the HIF-
presenting factor to the proteasome in breast cancer progres-
sion54. Nevertheless, the fact that P4HA1 expression correlates
with HIF-1 activation in breast cancer tissues suggests that
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Fig. 7 Inhibition of P4HA1 sensitizes TNBC to docetaxel in vivo. a Tumor growth curve of control and P4HA1-silenced MDA-MB-231 cells implanted mice
treated with docetaxel. Results are presented as mean ± SEM; n= 10; **p < 0.01. The data were analyzed by one-way ANOVA test. b Tumor growth curve
of MDA-MB-231 cells implanted mice treated with P4H inhibitor DHB (40mg/kg) and/or Doc (docetaxel) (10mg/kg). The DHB treatment started from
day 1 to day 21 in the tumor growth curve. Results are presented as mean ± SEM; n= 8. c HE images, IHC staining images (HIF-1α, Ki-67, active-caspase-3),
and Masson’s trichrome staining images of tumor sections from mice treated with DHB and/or Doc. Bar: 20 µm. d, e Quantification of cell proliferation and
apoptosis in tumor sections from mice treated with DHB and/or Doc; n= 4; **p < 0.01, one-way ANOVA test. f Representative HE images and
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hyperactivation of HIF-1α in TNBC is at least partially induced
by P4HA1.
Tumor-initiating cells have the ability to form tumors after
xenotransplantation and are the driver of cancer progression55,56.
We showed that P4HA1 expression was upregulated in tumor-
initiating cell-enriched populations. P4HA1 expression promoted
tumorsphere formation, expanded the ALDH-high cell popula-
tion, and enhanced cancer cell colonization in the distant organs.
These results suggest that upregulation of P4HA1 contributes to
the survival or self-renewal of tumor-initiating cells. Self-renewal
of stem cells relies primarily on glycolysis and the pentose
phosphate pathway57. This process is also associated with a
reduction of oxidative phosphorylation. We found that P4HA1
expression inhibited oxidative phosphorylation and reduced ROS
levels in breast cancer cells. The majority of ROS are generated in
mitochondria during oxidative phosphorylation. ROS directly
react with various proteins, such as kinases, phosphatases, or
transcription factors. Reduced ROS levels are critical for survival
and self-renewal of stem cells;58 therefore, ROS are considered as
crucial mediators of metabolism and stem cell fate decisions. HIF-
1 has been identified as a major metabolic regulator in stem
cells57, and activation of the HIF-1 pathway induces glycolysis
and suppresses oxidative phosphorylation59,60. We found that
P4HA1 expression reduced oxidative phosphorylation and
induced HIF-1-targeted gene expression in breast cancer cells.
The rescue experiments further demonstrate that P4HA1 inhib-
ited ROS generation and oxidative phosphorylation through the
HIF-1 pathway. These results identified a pathway that collagen
P4H modulates cell metabolism and subsequently enhances
tumor-initiating cell activity.
Chemotherapy is widely used for TNBC treatment. It has been
shown that treatment with chemotherapeutic agents increases the
tumor-initiating cell population in cancer tissue26,46. The tumor-
initiating cells with enhanced ALDH expression and ATP-
binding cassette transporter activity further promote the devel-
opment of chemoresistance61. Thus, targeting tumor-initiating
cells is a promising approach to overcome chemoresistance55.
Silence or inhibition of P4HA1 activity reduced ALDH-high cell
population and enhanced inhibitory activity of DOC and DOX in
CD44+/CD24–/low cells. We also demonstrate that combined
treatment with the P4Hi and DOC induces regression of TNBC in
PDOs and orthotopic breast cancer models. Moreover, increased
P4HA1 expression correlates with poor prognosis and chemore-
sistance in TNBC patients. These results suggest that collagen
P4HA1 is a potential drug target and prognosis marker for
TNBC. Therefore, developing highly specific and potent collagen
P4Hi may hold the key to overcome chemoresistance and
improve TNBC treatment. Roles of signal transducer and acti-
vator of transcription 3 (STAT3) in chemoresistance are well
established62,63. However, the unbiased gene co-expression ana-
lysis did not detect the association between P4HA1 and the
STAT3 pathway or gene signature in human breast cancer tissues.
Currently we do not have strong data to support that P4HA1
promotes chemoresistance through the STAT3 pathway.
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Fig. 8 P4HA1 expression is associated with chemoresistance and activation of the HIF-1 gene signature. a, b Growth of patient-derived tumor organoids
(PDOs) in the 3D laminin-rich ECM gel was assessed after docetaxel (DOC), doxorubicin (DOX), and/or P4HA inhibitor (DHB) treatment; results are
presented as mean ± SEM. n= 89; **p < 0.01, one-way ANOVA test. Bar, 40 µm. c Tumor growth curve of PDX treated with DHB (40mg/kg) and/or DOC
(10mg/kg); n= 5; **p < 0.01; *p < 0.05, one-way ANOVA test. d The association of P4HA1 expression with recurrence-free survival was assessed by
analyzing the mRNA levels in basal-like/TNBC tissues, n= 580, Kaplan–Meier survival analysis. e The association of P4HA1 expression with recurrence-
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P4HA1 expression is induced during breast cancer develop-
ment and TNBC progression. However, it is unclear how P4HA1
expression is induced in TNBC. P4HA1 expression is induced by
HIF-1α under hypoxia condition64. Activation of the HIF-1
pathway enhances collagen production and tissue fibrosis. These
results suggest a positive feedback loop between collagen hydro-
xylation and the HIF-1 pathway, and this feedback loop may be
critical for the integration of collagen deposition and TNBC
progression. Interestingly, silencing HIF-1α partially inhibited
P4HA1 expression in TNBC cells7, suggesting that HIF-1 is not
the only pathway that regulates P4HA1 expression during breast
cancer progression. TNBC is associated with activation of the
epithelial–mesenchymal transition (EMT) program65. It is plau-
sible that P4HA1 expression is regulated by EMT drivers during
breast cancer progression.
In the present study, we have identified a novel function of
collagen P4H in regulating the HIF-1 pathway and tumor-
initiating cells in TNBC. These findings fill a critical gap in our
knowledge about the HIF-1 regulation and chemoresistance
during TNBC progression. We propose that targeting collagen
P4H provides a potential strategy to improve TNBC treatment.
Methods
All the reagents used in this study were listed in Supplementary Table 2
Quantitative RT-PCR. Total RNA was extracted from cells using TRIzol reagent
(Invitrogen, 15-596-018). Complementary DNA was synthesized using the
SuperScript™ III First-Strand Synthesis System (Invitrogen, 18-080-051) from 1.0
μg RNA samples. Quantitative RT-PCRs were carried out with SYBR Green PCR
Master Mix reagents using an StepOnePlus™ Real-Time PCR System (Thermo
Fisher Scientific, 4376600). Thermal cycling was conducted for 30 s at 95 °C, fol-
lowed by 40 cycles of 5 s amplification at 95 °C, 30 s at 55 °C, and 15 s at 72 °C. The
relative quantification of gene expression for each sample was analyzed by the
threshold cycle (CT) method. Information of primers used for amplification of
PDK1, LDHA, and 18S ribosomal RNA is given in Supplementary Table 3.
Western blot assays. Cells were lysed in 2% sodium dodecyl sulfate (SDS) in
phosphate-buffered saline (PBS) buffer containing phosphatase and protease
inhibitor cocktails (EMD Millipore, 539131). Protein concentration was measured
using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, 23227). Equal
amounts of protein lysates or cell conditional medium (normalized to cell num-
bers) were subjected to SDS gel electrophoresis, immunoblotted with primary
antibodies, and horseradish peroxidase (HRP)-conjugated or DyLight 680/800-
conjugated secondary antibodies. Western blot results were quantified by using the
AlphaInnotech analysis software. The secondary antibodies used in this study were
as follows: HRP-conjugated goat anti-rabbit IgG secondary antibody (Thermo
Fisher Scientific, 31460), HRP-conjugated goat anti-mouse IgG secondary antibody
(Thermo Fisher Scientific, 31440), HRP-conjugated rabbit anti-goat IgG secondary
antibody (Thermo Fisher Scientific, 31402); DyLight 680-conjugated goat anti-
rabbit IgG secondary antibody (Thermo Fisher Scientific, 35569), DyLight 800-
conjugated goat anti-mouse IgG secondary antibody (Thermo Fisher Scientific,
SA5-35521), DyLight 680-conjugated donkey anti-goat IgG secondary antibody
(Thermo Fisher Scientific, SA5-10090). The primary antibodies used in this study
were listed in Supplementary Table 4. Uncropped scans of important blots are
included in the Supplementary Figure 10–15.
Luciferase reporter assays. Luciferase reporter construct containing three HREs
was purchased from Addgene (26731). HRE-luciferase reporter plasmid and
Renilla luciferace vector were transiently transfected into control and P4HA1-
silenced MDA-MB 231 cells. Cell lysate was collected for the luciferase assay
analysis 48 h after transfection.
The ODD-luciferase reporter construct consisting of a firefly luciferase gene
fused to the hydroxylation-dependent degradation region of HIF-1α was purchased
from Addgene (18965). The ODD-luciferase reporter plasmid and Renilla
luciferace vector were transiently transfected into control and P4HA1-silenced
MDA-MB-231 cells, or P4HA1-expressing and P4HB-expressing MCF10A cells.
For rescue experiments, the ODD-luciferase reporter plasmid and Renilla luciferace
vector were transiently transfected into P4HA1-silenced MDA-MB-231 cells
followed by succinate treatment or P4HA1-expressing and P4HB-expressing-
MCF10A cells followed by α-KG treatment.
Immunoprecipitation. HIF-1α expression plasmid pCDH1-HIF-1α(wild-type)-
Flag, UB-HA plasmid, and shctrl-transfected or shP4HA1-transfected 293FT cells
were lysed with ice-cold hypotonic gentle lysis buffer (10 mM Tris-HCl (pH 7.5),
10 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, phosphatase and protease inhibitor
cocktails (EMD Millipore, 539131)) and incubated on ice for 10 min. Five moles of
NaCl was added to the cell lysis buffer to a concentration of 150 mM. The protein
complexes were pulled down with anti-Flag M2 affinity gel (Sigma-Aldrich,
A2220), and the immunoprecipitated protein was eluted for western blot analysis.
Stable isotope tracers experiment. When cells in 10 cm plates were about 70%
confluent in the cell growth medium, the cell growth medium was changed to
stable isotope tracer medium containing [U-13C]-glucose (CLM-1396-PK) at
0.45%, 10% dialyzed fetal bovine serum, and 1× penicillin–streptomycin in glucose-
free Dulbecco's modified Eagle's medium (DMEM)). The cells were incubated in a
tracer medium with 5% CO2 at 37 °C and recorded the start time. At the end of the
tracer treatment (24 h later), the cell culture plates were placed on ice, the medium
was removed, and the plates were washed three times with ice-cold PBS. One
milliliter cold CH3CN, 0.55 ml H2O, and 0.2 ml 0.2 mM Tris-HCl (pH 8.0) were
added into each plate and cells were scraped and collected in 15 ml tubes. One
milliliter cold chloroform was added in the 15 ml tube containing cell samples.
After shaking 60 times and vortexed, the 15 ml tube containing cell samples was
centrifuged at 3500 × g for 20 min at 4 °C. The top layer (polar extraction) was
transferred to the pre-weight 15 tubes with fine tip pipette. Exact weight for the
polar extraction was recorded and two aliquots of 1/8 of the total polar extract
volume were transferred to 1.5 ml glass vials for gas chromatography-mass spec-
trometry analysis. Two aliquots of 1/16 of the total polar extract volume were
transferred to 0.5 ml screw top microfuge tubes for Fourier transform-mass spec-
trometry analysis. The remaining polar extract was aliquoted into two 2.0 ml
microfuge tubes for NMR analysis. The middle layer (protein) was transferred to
pre-weight 1.5 ml Eppendorf tube and washed with 500 μl cold methanol. After
centrifugation at 18,407 × g for 20 min at 4 °C, the supernatant was discarded and
the protein was dried using the SpeedVac (Vacufuge Plus, Eppendorf). The dry
protein was weighted and store at −80 °C.
Seahorse assay. MDA-MB-231 cells (shcontrol, shP4HA1, or shP4HA1 plus HIF-
1α PPAA) and MCF10A cells (control or P4HA1, P4HB expressing) were seeding
to a 96-well Seahorse XF Cell Culture Microplate (10,000 cells per well). After 24 h,
the cell culture growth medium was changed to a pre-warmed assay medium and
the cell culture microplate was placed into a 37 °C non-CO2 incubator for 45 min
to 1 h prior to the assay. Then, the mitochondrial respiration (OCR) and glycolysis
(ECAR) were measured in the XF Analyzer according to the manual of Seahorse
XF Cell Mito Stress Test Assay (Seahorse Bioscience of Agilent Technologies).
α-KG quantification assay. According to the kit instructions (Abcam, ab83431),
MDA-MB-231 cells (shcontrol or shP4HA1) and MCF10A cells (control or
P4HA1, P4HB expressing) were washed with cold PBS and resuspended in 500 μl
ice-cold α-KG Assay Buffer on ice. Cells were homogenized quickly by pipetting up
and down a few times and then centrifuged for 2–5 min at 4 °C at 15,871 × g to
remove any insoluble material. Fifty microliters of α-KG standard or cell sample
was added to the well of 96-well plates. For each α-KG standard or cell sample, the
reaction mix (50 μl) was added and incubated for 30 min at 37 °C and protected
from light. The 96-well plates were measured on Spectra MRTM microplate
spectrophotometer (Dynex Technologies) at OD570 nm.
Succinate quantification assay. According to the kit instructions (Megazyme, K-
SUCC), MDA-MB-231 cells (shcontrol or shP4HA1) were washed with cold PBS
and resuspended in 300 μl ice-cold PBS. Sonicated for several seconds, 10 μl sample
or succinate standard was added to the well of 96-well plates. For each α-KG
standard or cell sample, a reaction mix (200 μl distilled water, 20 μl buffer, 20 μl
NADH, 20 μl ATP/PEP/CoA, 2 μl PK/L-LDH) was added and the absorbance (A1)
was read at OD340 nm after 3 min. After adding 2 μl succinyl-CoA synthetase, the
absorbance (A2) was read on a Spectra MRTM microplate spectrophotometer
(Dynex Technologies) at OD340 nm at the end of the reaction (6 min later). The
concentrations of succinate in samples were calculated by the ΔA method.
Cancer stem cell ALDH FACS analysis. According to the manual of ALDH
ALDEFLUOR™ Kit (Stemcell Technologies, 1700), cells were trypsinized and
resuspended in the ALDEFLUOR™ Assay Buffer at 1 × 106 cells/ml buffer. Five
microliters of the activated ALDEFLUOR™ reagent was added to and mixed well
with 1.0 ml cell sample (“Test” tube). Then, 0.5 ml of the mixture was immediately
transferred to a “control” tube by adding 5 μl of ALDEFLUOR™ DEAB reagent.
“Test” and “Control” samples were incubated for 45 min at 37 °C. After incubation,
samples were centrifuged and resuspended in 0.5 ml of ALDEFLUOR™ Assay
Buffer and kept on ice for FACS analysis. FACS analysis was done with Becton
Dickinson LSR II and data were analyzed by CellQuest Pro. Gates were set
according to unstained control and single-color control for fluorescein iso-
thiocyanate (FITC).
CD44/CD24 FACS analysis. To selected HMLE monoclones with mesenchymal
traits and in the expression of stem cell markers (CD44+/CD24−/low), 1000 HMLE
cells were passaged to a 100-mm culture dish. After the monocell clones' growth,
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cell clones with epithelial or mesenchymal morphology were picked and expanded.
The CD44/CD24 levels in these clones were examined by FACS analysis. HMLE
cells were trypsinized and resuspended (1 × 106 cells) in 100 μl HBSS buffer (0.137
M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.1% glucose, 0.44 mM KH2PO4, 1.3
mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3) containing 20 μl FITC mouse anti-
human CD24 (BD Biosciences, 555427). The mixture was incubated at room
temperature for 1 h and protected from light. Then, 10 μl phycoerythrin (PE)
mouse anti-human CD44 (BD Biosciences, 550989) was added to each sample and
incubated on ice for 20 min and protected from light. After incubation with
antibodies, samples were fixed with 2% paraformaldehyde (PFA) for 20 min at
room temperature. Samples were centrifuged and resuspended in 200 μl HBSS
buffer and kept on ice for FACS. FACS analysis was done with Becton Dickinson
LSR II and data were analyzed by CellQuest Pro. Gates were set according to
unstained control and single-color controls for FITC, PE, respectively.
ROS FACS analysis. According to the manual of CellROX Deep Red Flow
Cytometry Assay Kit (Life Technologies, C10491), cells were trypsinized and
resuspended in a complete growth medium at a concentration of 0.5 × 105 cells/ml.
The CellROX® Deep Red reagent was added to the cell samples at a final con-
centration of 500–1000 nM and incubated for 45 min at 37 °C and protected from
light. One microliter propidium iodide (1 mg/ml) was added to the cell samples
and incubated on ice for FACS analysis. FACS analysis was done with Becton
Dickinson LSR II and data were analyzed by CellQuest Pro. Gates were set
according to unstained control and single-color control for deep red.
Tumorsphere assay. Tissue culture plates were pretreated with poly (2-hydro-
xyethyl methacrylate) (12 mg/ml in 95% ethanol) overnight at 53 °C. Cells were
cultured on 2D plastic culture dish in a regular culture medium and trypsinized
according to the standard protocol. Cells were filtered by Cell Strainer (40 µm,
Corning®) to ensure a single-cell suspension. Viable cell number was calculated
after trypan blue staining using a hemocytometer. One milliter of tumorsphere
media (DMEM/F12 medium supplemented with B27 (1:50), epidermal growth
factor (20 ng/ml), basic fibroblast growth factor (20 ng/ml), insulin (5 μg/ml),
hydrocortisone (0.5 μg/ml), gentamycin (100 µg/ml)) were added into each well of
a non-adherent 12-well culture plate. Single-cell suspension was plated at an
appropriate density in triplicate. After incubating for 5 days in a humidified
atmosphere with 5% CO2 at 37 °C without moving or disturbing the plates, the
number of tumorspheres >50 μm diameter was counted using a microscope.
Tumorsphere-forming efficiency (%) is calculated as follows: number of tumor-
spheres per well/number of cells seeded per well × 100.
Cell proliferation assay. MDA-MB-231 cells or HMLE cells were seeded to a 96-
well cell culture plate (3000 cells per well). After 24 h, P4Hi or combination with
DOC, cisplatin was added to the cell culture medium. After a 2-day treatment, 10 μl
of the CCK-8 solution was added to each well of the plate, according the
instruction of the Cell Counting Kit-8 (Sigma-Aldrich, 96992). The plate was
incubated for 1–4 h at 37 °C in the cell incubator . The 96-well plate was measured
on Spectra MRTM microplate spectrophotometer (Dynex Technologies) at OD450
nm. For each cell clone, the OD450 values in the drug treatment group were
normalized to the value in the control group.
In Vivo xenograft experiments. Six-week-old female SCID mice were randomly
grouped and injected with 1 × 106 shcontrol or shP4HA1 MDA-MB-231/Luc cells
in mammary fat pads. Mice were treated with DOC (10 mg/kg) every 4 days by
intraperitoneal injection when tumors reached 60–70 mm3 . Tumors were mea-
sured with a caliper every 2 days to analyze tumor growth. At the experimental
endpoint, tumors and lung tissues were harvested and fixed with 4% PFA for
paraffin-embedded section.
Six-week-old female SCID mice were injected with 1 × 106 MDA-MB-231 cells
in mammary fat pads and randomly grouped into four groups: group 1, control;
group 2, P4H inhibitor (P4Hi); group 3, DOC; group 4, P4Hi and DOC. DHB has
been safely used in vivo to inhibit collagen deposition at 40 mg/kg weight per day7.
It also inhibits cancer metastasis at this concentration7. Thus, we chose this
inhibitor for the xenograft experiments. DHB (40 mg/kg) was administered every
day by intraperitoneal injection, 2 weeks after tumor cell injection. Mice were
treated with DOC (10 mg/kg) every 4 days by intraperitoneal injection when
tumors reached 60–70 mm3. Tumors were measured with a caliper every 2 days to
analyze tumor growth. After treatment with four doses of DOC (day 21), the
tumors were kept in mice to examine the tumor regrowth without drug treatment.
To examine the effects of drug treatments on cell proliferation and apoptosis, we
performed surgery to remove tumors at day 21 for hematoxylin and eosin (H&E)
and IHC analyses. The mice were kept for another month after the surgery to
detect metastasis to lung. At the experimental endpoint, lung tissues were harvested
and fixed with 4% PFA for H&E analyses.
Six-week-old female SCID mice were randomly grouped and injected with 1 ×
106 (in 200 µl PBS) shcontrol or shP4HA1 MDA-MB-231/Luc cells via the tail vein.
To detect lung metastasis, bioluminescent images were taken 2 weeks after cancer
cell injection with the IVIS Spectrum. Mice were sacrificed 5 weeks after cancer cell
injection.
All procedures were performed within the guidelines of the Division of
Laboratory Animal Resources at the University of Kentucky.
Human breast cancer PDO experiments. Human breast cancer tissues were
minced with scalpels until finely chopped, and then were transferred to a 50 ml
conical vial using a cell lifter. The minced tumor tissues were incubated with 1 mg/
ml type IV collagenase (Sigma #C5138) and 100 U/ml hyaluronidase (Sigma
#H3884) in DMEM/F12 at 37 °C for 2 h. Digested tumor fragments were pelleted
for 3 min at 100 × g, and the supernatant was discarded. Large tumor fragments
were removed by 100 μm filter. Isolated primary tumor organoids were cultured on
top of a 3D laminin-rich ECM. In general, primary tumor organoids were seeded
on top of a thin gel of Engelbreth–Holm–Swarm tumor extract (Matrigel; BD
Biosciences), and a medium containing 5% Matrigel was added. The P4Hi and/or
chemotherapeutic agents were added after 24 h. The diameter of tumor organoids
was measured under the microscope every day for the next 8 days.
Human breast cancer PDX experiments. Human breast cancer tissues were
minced with scalpels until finely chopped, and then were mixed with Matrigel. The
mixture of minced human breast cancer tissue with Matrigel was injected sub-
cutaneously to the NOD-SCID IL2Rgammanull female mice (Jackson Laboratory)
(F1). When the tumor diameter reached ~200 mm, the tumor was collected and
minced with scalpels until finely chopped, and then were mixed with Matrigel.
The mixture of minced human breast cancer tissue and Matrigel was injected
subcutaneously to the 20 NOD-SCID IL2Rgammanull female mice (Jackson
Laboratory) (F2). Tumors were measured with a caliper every 2 days to analyze
tumor growth. All mice were randomly grouped into four groups: group 1, control;
group 2, P4Hi (DHB); group 3, DOC; group 4, P4Hi (DHB) and DOC. P4Hi
(DHB, 40 mg/kg) was administered every day by intraperitoneal injection, 2 weeks
after tumor cell injection. Mice were treated with DOC (10 mg/kg) every 4 days by
intraperitoneal injection when tumors reached ~100 mm3. At the experimental
endpoint, tumors and lung tissues were harvested and fixed with 4% PFA for
paraffin-embedded section.
PDX and PDO experiments involved human breast cancer patients. The studies
were approved by the Committee on the Use of Humans as Experimental Subjects
of University of Kentucky, IRB protocol # 15–0767-P6H. All clinical samples were
collected with written informed consent from patients in the Markey Cancer
Center at the University of Kentucky. Cell culture, Immunohistochemistry and
Masson’s trichrome staining are included in the Supplementary Methods.
Patient survival analysis and other statistical analysis. To address the clinical
relevance of enhanced P4HA1 expression, we assessed the association between
mRNA levels of P4HA1 and patient survival using the published microarray data
generated from 580 human TNBC tissue samples49. Tumor samples were equally
grouped into low and high P4HA1 expression based on the mRNA levels. Sig-
nificant differences in overall survival time were assessed with the Kaplan–Meier
survival analysis and the Cox proportional hazard (log-rank) test. The activation of
the HIF-1 gene signature was evaluated based on the expression of 58 HIF-1 target
genes51. The correlation between P4HA1 expression and activation of the HIF-1
gene signature was analyzed using the microarray dataset generated from human
breast cancer tissues66.
All experiments were repeated at least twice. Results were reported as mean ± S.
E.M.; the significance of difference was assessed by χ2, independent Student’s t test,
or one-way analysis of variance (ANOVA) with SigmaPlot 12.3 (Systat Software
Inc., San Jose, CA, USA). P < 0.05 represents statistical significance and P < 0.01
represents sufficiently statistical significance. All reported P values were from two-
tailed tests.
Data availability
Metabolic data are available to the community via the Metabolomics Workbench
(http://www.metabolomicsworkbench.org) under project ID PR000703 (https://doi.
org/10.21228/m8t10p). All the other data generated in this study are available
within the article and its Supplementary Information Files and from the corre-
sponding author upon reasonable request.
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